

## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

**Date: 30 May 2026**

To  
Corporate relationship Department,  
BSE Limited,  
1<sup>st</sup> Floor, Rotunda Building  
P.J Towers Dalal Street, Fort,  
Mumbai 400001

National Stock Exchange of India, Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block, Bandra-Kurla Complex,  
Bandra (E),  
Mumbai 400051

**Stock Code: BSE – 530549 / NSE – SHILPAMED**

Dear Sir/Ma'am,

**Sub: Intimation under regulation 30 of SEBI (LODR) Regulations 2015**

### **USFDA Inspection of Shilpa Medicare Ltd. Unit VI, Dabaspeta, Bengaluru**

This is to notify that the USFDA conducted Pre-Approval Inspection (PAI) at Unit VI of Shilpa Medicare Limited, located at Plot No.29/A, Sompura, Phase 4, Avarehalli Industrial Area, Dabaspeta, Bengaluru, Karnataka from 25 May 2026 to 29 May 2026. The inspection ended with the issuance of FDA Form 483 with 5(five) procedural observations and none of which have been categorized as a repeat observation and not related to data integrity.

The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches.

Unit VI had previously undergone a USFDA GMP inspection and holds a Voluntary Action Indicated (VAI) status, reflecting the facility's strong track record of regulatory compliance. In addition to its USFDA approval, Unit VI holds accreditations from Europe- EMA, Saudi Arabia-SFDA, UK-MHRA, and Australia- TGA.

The Company shall respond comprehensively to the procedural observations within the stipulated time.

We do not expect this development to have any material impact on the current business operations or existing supplies from this facility.

**The details of the above Inspection (as required to be furnished pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30th January 2026) are enclosed as Annexure A.**

The above information is also available on the website of the Company [www.vbshilpa.com](http://www.vbshilpa.com)  
**For SHILPA MEDICARE LIMITED**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**

**Annexure A**

**Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated 30th January 2026.**

Sr. No.	Particulars	Details
1.	Name of the authority	United States Food and Drug Administration (US FDA), USA
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	<p>The United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) at Formulation facility located at Bengaluru.</p> <p>The inspection was completed on 29 May 2026 and at the conclusion, the USFDA has issued a Form 483 with 5 observations. These observations are procedural in nature.</p>
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	29 May 2026
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	<p>The inspection was completed on 29 May 2026 and at the conclusion, the USFDA issued Form 483 with 5 observations. These observations are procedural in nature.</p> <p>We will submit a comprehensive response to the USFDA within the stipulated timeline, addressing each observation with appropriate corrective and preventive actions. The Company is committed to maintaining the highest standards of quality and compliance across all its operations.</p>



Innovating for  
affordable healthcare

## *Shilpa Medicare Limited*

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: [info@vbshilpa.com](mailto:info@vbshilpa.com), Web: [www.vbshilpa.com](http://www.vbshilpa.com)

CIN: L85110KA1987PLC008739

5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	We do not expect this development to have any material impact on the current business operations or existing supplies from this facility.
---	--	---